Cold agglutinin disease as a new immune-related adverse event associated with anti-PD-L1s and its treatment with rituximab

被引：10

作者：

Dutertre, Martin ^{[1
]}

de Menthon, Mathilde ^{[1
]}

Noel, Nicolas ^{[1
]}

Albiges, Laurence ^{[2
]}

Lambotte, Olivier ^{[1
]}

机构：

[1] Hop Univ Paris Sud, AP HP, Serv Med Interne Immunol Clin, Le Kremlin Bicetre, France

[2] Univ Paris Saclay, Univ Paris Sud, Inst Gustave Roussy, Dept Oncol Med, F-94800 Villejuif, France

来源：

EUROPEAN JOURNAL OF CANCER | 2019年 / 110卷

关键词：

D O I：

10.1016/j.ejca.2019.01.009

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：21 / 23

页数：3

共 9 条

[1] Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline [J].

Brahmer, Julie R. ;

Lacchetti, Christina ;

Schneider, Bryan J. ;

Atkins, Michael B. ;

Brassil, Kelly J. ;

Caterino, Jeffrey M. ;

Chau, Ian ;

Ernstoff, Marc S. ;

Gardner, Jennifer M. ;

Ginex, Pamela ;

Hallmeyer, Sigrun ;

Chakrabarty, Jennifer Holter ;

Leighl, Natasha B. ;

Mammen, Jennifer S. ;

McDermott, David F. ;

Naing, Aung ;

Nastoupil, Loretta J. ;

Phillips, Tanyanika ;

Porter, Laura D. ;

Puzanov, Igor ;

Reichner, Cristina A. ;

Santomasso, Bianca D. ;

Seigel, Carole ;

Spira, Alexander ;

Suarez-Almazor, Maria E. ;

Wang, Yinghong ;

Weber, Jeffrey S. ;

Wolchok, Jedd D. ;

Thompson, John A. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) :1714-+

[2] Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper [J].

Champiat, S. ;

Lambotte, O. ;

Barreau, E. ;

Belkhir, R. ;

Berdelou, A. ;

Carbonnel, F. ;

Cauquil, C. ;

Chanson, P. ;

Collins, M. ;

Durrbach, A. ;

Ederhy, S. ;

Feuillet, S. ;

Francois, H. ;

Lazarovici, J. ;

Le Pavec, J. ;

De Martin, E. ;

Mateus, C. ;

Michot, J. -M. ;

Samuel, D. ;

Soria, J. -C. ;

Robert, C. ;

Eggermont, A. ;

Marabelle, A. .

ANNALS OF ONCOLOGY, 2016, 27 (04) :559-574

[3]

Delaney N, 2019, LANCET HAEMATOL, V6, pE48, DOI [10.1016/S2352-3026(18)30175-3, 10.1016/52352-3026(18)30175-3]

[4] Nivolumab-induced cold agglutinin syndrome successfully treated with rituximab [J].

Hasanov, Merve ;

Konoplev, Sergej N. ;

Hernandez, Cristhiam M. Rojas .

BLOOD ADVANCES, 2018, 2 (15) :1865-1868

[5] Exacerbation of autoimmune hemolytic anemia induced by the first dose of programmed death-1 inhibitor pembrolizumab: a case report [J].

Ogawa, Kenta ;

Ito, Jiro ;

Fujimoto, Daichi ;

Morita, Mari ;

Yoshizumi, Yuko ;

Ariyoshi, Koichi ;

Tomii, Keisuke ;

Katakami, Nobuyuki .

INVESTIGATIONAL NEW DRUGS, 2018, 36 (03) :509-512

[6] Autoimmune Hemolytic Anemia as a Complication of Nivolumab Therapy [J].

Palla, Amruth R. ;

Kennedy, Devin ;

Mosharraf, Hossain ;

Doll, Donald .

CASE REPORTS IN ONCOLOGY, 2016, 9 (03) :691-697

[7]

Shaikh H, 2018, BMJ CASE REP, V2018

[8] Incidence and long-term prognosis of papillary compared to clear cell renal cell carcinoma - A multicentre study [J].

Steffens, Sandra ;

Janssen, Martin ;

Roos, Frederik C. ;

Becker, Frank ;

Schumacher, Simon ;

Seidel, Christoph ;

Wegener, Gerd ;

Thueroff, Joachim W. ;

Hofmann, Rainer ;

Stoeckle, Michael ;

Siemer, Stefan ;

Schrader, Mark ;

Hartmann, Arndt ;

Kuczyk, Markus A. ;

Junker, Kerstin ;

Schrader, Andres J. .

EUROPEAN JOURNAL OF CANCER, 2012, 48 (15) :2347-2352

[9] Cold agglutinin disease [J].

Swiecicki, Paul L. ;

Hegerova, Livia T. ;

Gertz, Morie A. .

BLOOD, 2013, 122 (07) :1114-1121

← 1 →